This report, for health professionals, government agencies, and organizations, presents information about HIV/AIDS and TB. It provides epidemiological statistics concerning the relationship between HIV/AIDS and TB, including incidence, morbidity rates, and mortality rates. It discusses TB and HIV transmission, how HIV can facilitate the development of active TB, and recommendations for the prevention of TB among HIV-positive persons.
This technical update reviews the incidence and prevalence of HIV in correctional facilities around the world and explains how this morbidity rate impacts the general public. The risk factors for HIV transmission in correctional facilities are reviewed and include drug injection, unprotected sexual relations, tattooing, skin piercing, blood brotherhood rites, lack of education, TB, and overcrowding. Suggestions for preventing the transmission of HIV in correctional settings are presented.
This report describes approaches for managing patients with TB who are candidates for or who are undergoing protease inhibitor therapy and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued. Protease inhibitors interact with rifamycin derivatives, which are used to treat and prevent the mycobacterial infections commonly observed in patients with the HIV. The report provides background information on the management of TB and the three treatment options currently available for these patients.
This report in the form of a notice to readers states that CDC in conjunction with the American Thoracic Society expects to issue new guidelines on screening and preventive therapy for TB that will include a recommendation on the use of the two-month regimen of daily rifampin and pyrazinamide (2RZ) as an alternative to 12-month isoniazid for prevention of TB in HIV-negative persons for whom preventive therapy is indicated. A comparative trial of the 2RZ regimen in HIV-negative persons has not been conducted.